pharmacokinetics new2

Upload: riddhi-gandhi

Post on 10-Apr-2018

240 views

Category:

Documents


0 download

TRANSCRIPT

  • 8/8/2019 Pharmacokinetics New2

    1/40

  • 8/8/2019 Pharmacokinetics New2

    2/40

    Dose

    PlasmaC

    oncentration

    0 1 2 3 4 5 6 7 8 90

    2

    4

    6

    8

    10

    12

    TOXIC RANGE

    THERAPEUTIC RANGE

    SUB-THERAPEUTIC

  • 8/8/2019 Pharmacokinetics New2

    3/40

    DISPOSITION OF DRUGS

    The disposition of chemicals entering the body (from C.D. Klaassen, Casarett and DoullsToxicology, 5th ed., New York: McGraw-Hill, 1996).

  • 8/8/2019 Pharmacokinetics New2

    4/40

    Bound Free Free Bound

    LOCUS OF ACTION

    RECEPTORS

    TISSUE

    RESERVOIRS

    SYSTEMICCIRCULATION

    Free Drug

    Bound Drug

    ABSORPTION EXCRETION

    BIOTRANSFORMATION

  • 8/8/2019 Pharmacokinetics New2

    5/40

  • 8/8/2019 Pharmacokinetics New2

    6/40

    Dose

    PlasmaC

    oncentration

    0 1 2 3 4 5 6 7 8 90

    2

    4

    6

    8

    10

    12

    TOXIC RANGE

    THERAPEUTIC RANGE

    SUB-THERAPEUTIC

  • 8/8/2019 Pharmacokinetics New2

    7/40

    Bound Free Free Bound

    LOCUS OF ACTION

    RECEPTORS

    TISSUE

    RESERVOIRS

    SYSTEMICCIRCULATION

    Free Drug

    Bound Drug

    ABSORPTION EXCRETION

    BIOTRANSFORMATION

  • 8/8/2019 Pharmacokinetics New2

    8/40

    Bioavailability

    Definition: the fraction of the administered

    dose reaching the systemic circulation

    for i.v.: 100%

    for non i.v.: ranges from 0 to 100%

    e.g. lidocaine bioavailability 35% due todestruction in gastric acid and liver metabolism

    First Pass Effect

  • 8/8/2019 Pharmacokinetics New2

    9/40

    Bioavailability

    Dose

    Destroyed

    in gut

    Not

    absorbed

    Destroyed

    by gut wall

    Destroyed

    by liver

    to

    systemic

    circulation

  • 8/8/2019 Pharmacokinetics New2

    10/40

    PRINCIPLEPRINCIPLE

    For drugs taken by routes other than the

    i.v. route, the extent of absorption and

    the bioavailability must be understood in

    order to determine what dose will induce

    the desired therapeutic effect. It will also

    explain why the same dose may cause atherapeutic effect by one route but a

    toxic or no effect by another.

  • 8/8/2019 Pharmacokinetics New2

    11/40

    Drugs appear to distribute in the body as if itwere a single compartment. The magnitude of

    the drugs distribution is given by the apparentvolume of distribution (Vd).

    Vd = Amount of drug in body Concentration in Plasma

    PRINCIPLEPRINCIPLE

    (Apparent) Volume of Distribution:

    Volume into which a drug appears to distribute with

    a concentration equal to its plasma concentration

  • 8/8/2019 Pharmacokinetics New2

    12/40

  • 8/8/2019 Pharmacokinetics New2

    13/40

    Drug L/Kg L/70 kg

    Sulfisoxazole 0.16 11.2Phenytoin 0.63 44.1

    Phenobarbital 0.55 38.5

    Diazepam 2.4 168

    Digoxin 7 490

    Examples of apparent Vds for

    some drugs

  • 8/8/2019 Pharmacokinetics New2

    14/40

    K I D N E

    f i l t r a t i os e c r e t i( r e a b s o r p t i

    L I V E R

    m e t a b os e c r e t i

    L U N Ge x h a l a

    O T H Em o t h e r '

    s w e a t , s

    E l i m i n a t i o

    o f d r u g s f r o

    M

    A

    J

    O

    R

    MI

    N

    O

    R

  • 8/8/2019 Pharmacokinetics New2

    15/40

    Elimination by the Kidney

    Excretion - major1) glomerular filtration

    glomerular structure, size constraints,protein binding

    2) tubular reabsorption/secretion

    -acidification/alkalinization,

    - active transport, competitive/saturable,

    organic acids/bases -protein binding

    Metabolism - minor

  • 8/8/2019 Pharmacokinetics New2

    16/40

    Elimination by the Liver

    Metabolism - major1) Phase I and II reactions

    2) Function: change a lipid soluble to morewater soluble molecule to excrete in kidney

    3) Possibility of active metabolites withsame or different properties as parent

    molecule

    Biliary Secretion active transport, 4 categories

  • 8/8/2019 Pharmacokinetics New2

    17/40

    The enterohepatic shunt

    Portal circulation

    Liver

    gall bladder

    Gut

    Bile

    duct

    Drug

    Biotransformation;

    glucuronide

    produced

    Bile formation

    Hydrolysis by

    beta glucuronidase

  • 8/8/2019 Pharmacokinetics New2

    18/40

    Dose

    PlasmaC

    oncentration

    0 1 2 3 4 5 6 7 8 90

    2

    4

    6

    8

    10

    12

    TOXIC RANGE

    THERAPEUTIC RANGE

    SUB-THERAPEUTIC

  • 8/8/2019 Pharmacokinetics New2

    19/40

    0

    2

    4

    6

    8

    10

    12

    14

    0 5 10 15 20

    TIME (hours)

    Plasm

    aco

    ncentratio

    n

    Influence of Variations in Relative Rates of

    Absorption and Elimination on Plasma

    Concentration of an Orally Administered Drug

    Ka/Ke=10

    Ka/Ke=0.1

    Ka/Ke=0.01

    Ka/Ke=1

  • 8/8/2019 Pharmacokinetics New2

    20/40

    Elimination

    Zero order: constant rate of eliminationirrespective of plasma concentration.

    First order: rate of elimination proportional toplasma concentration. ConstantFraction of drugeliminated per unit time.

    Rate of elimination Amount

    Rate of elimination = Kx Amount

  • 8/8/2019 Pharmacokinetics New2

    21/40

    Zero Order Elimination

    Pharmacokinetics of Ethanol Ethanol is distributed in total body water.

    Mild intoxication at 1 mg/ml in plasma.

    How much should be ingested to reach it?Answer: 42 g or 56 ml of pure ethanol (VdxC)

    Or 120 ml of a strong alcoholic drink like whiskey

    Ethanol has a constant elimination rate = 10 ml/h

    To maintain mild intoxication, at what rate mustethanol be taken now?

    at 10 ml/h of pure ethanol, or 20 ml/h of drink.

    Rarely Done DRUNKENNES Coma Death

  • 8/8/2019 Pharmacokinetics New2

    22/40

  • 8/8/2019 Pharmacokinetics New2

    23/40

    Time

    Plasm

    aC

    oncentratio

    n

    0 1 2 3 4 5 61

    10

    100

    1000

    10000

    First Order Elimination

    logCt = logC0 - Kel . t

    2.303

  • 8/8/2019 Pharmacokinetics New2

    24/40

  • 8/8/2019 Pharmacokinetics New2

    25/40

    lnCt = lnCo Kel .t

    When t = 0, C = C0, i.e., the concentration at

    time zero when distribution is complete and

    elimination has not started yet. Use this value

    and the dose to calculate Vd.

    Vd = Dose/C0

  • 8/8/2019 Pharmacokinetics New2

    26/40

    lnCt = lnC0 Kel .t

    When Ct = C0, then Kel .t = 0.693. This is the

    time for the plasma concentration to reach half

    the original, i.e., the half-life of elimination.

    t1/2 = 0.693/Kel

  • 8/8/2019 Pharmacokinetics New2

    27/40

    PRINCIPLEPRINCIPLE

    Elimination of drugs from the

    body usually follows first order

    kinetics with a characteristic

    half-life (t1/2) and fractional rateconstant (Kel).

  • 8/8/2019 Pharmacokinetics New2

    28/40

    First Order Elimination

    Clearance:volume of plasma cleared of drugper unit time.

    Clearance = Rate of elimination plasma conc. Half-life of elimination:time for plasma

    conc. to decrease by half.

    Useful in estimating:

    - time to reach steady state concentration.- time for plasma concentration to fall after

    dosing is stopped.

  • 8/8/2019 Pharmacokinetics New2

    29/40

    IN

    OUT

    Blood Flow = Q

    CA CV

    BLOOD

    BLO

    OD

    ELIMINATED

    Rate of Elimination = QCA QCV = Q(CA-CV)

    Liver Clearance = Q(CA-CV)/CA = Q x EFSIMILARLY FOR

    OTHER ORGANS

    Renal Clearance = UxV/Px

    Total Body Clearance = CLliver

    + CLkidney

    + CLlungs

    + CLx

  • 8/8/2019 Pharmacokinetics New2

    30/40

    Rate of elimination = Kel x Amount in body

    Rate of elimination = CL x Plasma Concentration

    Therefore,

    Kel x Amount = CL x Concentration

    Kel = CL/Vd

    0.693/t1/2 = CL/Vd

    t1/2 = 0.693 x Vd/CL

  • 8/8/2019 Pharmacokinetics New2

    31/40

    PRINCIPLEPRINCIPLE

    The half-life of elimination of a drug (and

    its residence in the body) depends on its

    clearance and its volume of distribution

    t1/2 is proportional to Vd

    t1/2 is inversely proportional to CL

    t1/2 = 0.693 x Vd/CL

  • 8/8/2019 Pharmacokinetics New2

    32/40

    Multiple dosing

    On continuous steady administration of a drug, plasmaconcentration will rise fast at first then more slowly andreach a plateau, where:

    rate ofadministration = rate of eliminationie.steady state is reached.

    Therefore, at steady state:

    Dose (Rate of Administration) = clearance x plasma conc.

    Or

    If you aim at a target plasma level and you know the

    clearance, you can calculate the dose required.

  • 8/8/2019 Pharmacokinetics New2

    33/40

    Constant Rate of Administration (i.v.)

  • 8/8/2019 Pharmacokinetics New2

    34/40

    0

    1

    2

    3

    4

    5

    6

    7

    0 5 10 15 20 25 30

    Time

    Plasm

    aConcen

    tration

    Repeated doses

    Maintenance dose

    Therapeutic

    level

    Single dose

    Loading dose

  • 8/8/2019 Pharmacokinetics New2

    35/40

    Concentration due to a single dose

    Concentration due to

    repeated doses

    The time to reach steady

    state is ~4 t1/2s

  • 8/8/2019 Pharmacokinetics New2

    36/40

    Pharmacokinetic parameters

    Volume of distribution Vd= DOSE / C

    0

    Plasma clearance Cl = Kel.V

    d

    plasma half-life t1/2= 0.693 / Kel

    Bioavailability (AUC)x/ (AUC)

    iv

    Get equation of regression line; from it get Kel , C0 , and AUC

  • 8/8/2019 Pharmacokinetics New2

    37/40

    But C x dt = small area under the curve. For total

    amount eliminated (which is the total given, or the

    dose, if i.v.), add all the small areas = AUC.

    Dose = CL x AUC and Dose x F = CL x AUC

    dC/dt = CL x C

    dC = CL x C x dt

  • 8/8/2019 Pharmacokinetics New2

    38/40

    0

    1 0

    2 0

    3 0

    4 0

    5 0

    6 0

    7 0

    0 2 4 6 8 1 0

    Plasm

    aco

    nce

    ntrati

    on

    Time (hours)

    Bioavailability (AUC)o(AUC)iv

    =

    i.v. route

    oral route

  • 8/8/2019 Pharmacokinetics New2

    39/40

    Daily Dose (mg/kg)

    PlasmaD

    rug

    Concentrat io

    n(m

    g/L

    )

    0 5 10 150

    10

    20

    30

    40

    50

    60

    Variability in Pharmacokinetics

  • 8/8/2019 Pharmacokinetics New2

    40/40

    PRINCIPLEPRINCIPLE

    The absorption, distribution and

    elimination of a drug are qualitativelysimilar in all individuals. However, for

    several reasons, the quantitative aspects

    may differ considerably. Each person

    must be considered individually and

    doses adjusted accordingly.